ETF Holdings Breakdown of BCRX

News associated with BCRX

Mariner LLC Grows Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Mariner LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,258 shares of the biotechnology company’s stock after purchasing an additional 3,224 shares during the quarter. […] - 2025-05-09 08:08:42

BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $17.00 Price Target at Needham & Company LLC

BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) had its price target lifted by Needham & Company LLC from $15.00 to $17.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Wedbush assumed coverage on […] - 2025-05-09 07:26:42

Tudor Investment Corp ET AL Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Tudor Investment Corp ET AL bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 99,450 shares of the biotechnology company’s stock, valued at approximately $748,000. A number of other institutional […] - 2025-05-08 09:44:51

JPMorgan Chase & Co. Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its target price lifted by JPMorgan Chase & Co. from $10.00 to $13.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 28.97% […] - 2025-05-08 08:04:48

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Earnings Beat

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report)’s stock price gapped up before the market opened on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $8.93, but opened at $9.80. BioCryst Pharmaceuticals shares last traded at $10.03, with a volume of 5,915,215 shares changing hands. The biotechnology […] - 2025-05-07 05:20:57

Investors Buy Large Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 2,675 call options on the company. This represents an increase of approximately 174% compared to the average daily volume of 975 call options. BioCryst Pharmaceuticals Price Performance Shares of BCRX stock opened at […] - 2025-05-07 05:20:55

Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $16.13

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price target among […] - 2025-05-06 05:46:52

XTX Topco Ltd Sells 10,601 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

XTX Topco Ltd lowered its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 33.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,069 shares of the biotechnology company’s stock after selling 10,601 shares during the period. XTX Topco Ltd’s holdings in […] - 2025-04-29 08:22:54

Russell Investments Group Ltd. Buys 12,941 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Russell Investments Group Ltd. boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 86.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,966 shares of the biotechnology company’s stock after acquiring an additional 12,941 shares during the quarter. Russell […] - 2025-04-25 08:54:49

Legal & General Group Plc Has $2.07 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Legal & General Group Plc raised its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 3.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 275,083 shares of the biotechnology company’s stock after acquiring an additional 10,199 shares during the period. Legal & General Group […] - 2025-04-25 08:12:54

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Invesco Ltd.

Invesco Ltd. boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 6.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,072,600 shares of the biotechnology company’s stock after purchasing an additional 67,492 shares during the period. Invesco Ltd. owned about 0.52% of BioCryst Pharmaceuticals […] - 2025-04-25 07:36:53

Renaissance Technologies LLC Decreases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Renaissance Technologies LLC lessened its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 7.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 545,021 shares of the biotechnology company’s stock after selling 44,059 shares during the quarter. Renaissance Technologies LLC’s holdings in BioCryst Pharmaceuticals were worth $4,099,000 at the end of the most […] - 2025-04-22 08:04:51

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 51.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 167,957 shares of the biotechnology company’s stock after buying an additional 56,930 shares during […] - 2025-04-15 08:35:00

Norges Bank Invests $3.95 Million in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Norges Bank acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 524,804 shares of the biotechnology company’s stock, valued at approximately $3,947,000. A number of other […] - 2025-04-11 08:06:51

Arrowstreet Capital Limited Partnership Sells 27,818 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Arrowstreet Capital Limited Partnership trimmed its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 6.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 403,412 shares of the biotechnology company’s stock after selling 27,818 shares during the quarter. Arrowstreet Capital Limited […] - 2025-04-10 08:45:21

Vanguard Group Inc. Has $164.62 Million Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Vanguard Group Inc. increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 7.8% during the fourth quarter, HoldingsChannel reports. The fund owned 21,890,422 shares of the biotechnology company’s stock after acquiring an additional 1,583,826 shares during the quarter. Vanguard Group Inc. owned 0.11% of BioCryst Pharmaceuticals worth $164,616,000 as of its most […] - 2025-04-07 09:35:13

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Corebridge Financial Inc.

Corebridge Financial Inc. lowered its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 7.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 102,731 shares of the biotechnology company’s stock after selling 7,755 shares during the quarter. […] - 2025-04-07 08:06:57

Schroder Investment Management Group Acquires 438,887 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Schroder Investment Management Group lifted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 523.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 522,657 shares of the biotechnology company’s stock after acquiring an additional 438,887 shares […] - 2025-04-06 09:32:56

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Position Increased by Teacher Retirement System of Texas

Teacher Retirement System of Texas grew its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 25.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 58,291 shares of the biotechnology company’s stock after purchasing an additional 11,711 shares during the period. Teacher Retirement System of Texas’ holdings in BioCryst Pharmaceuticals were worth […] - 2025-04-01 08:14:55

Cibc World Markets Corp Acquires New Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Cibc World Markets Corp bought a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 19,338 shares of the biotechnology company’s stock, valued at approximately $145,000. Several other hedge funds have also added […] - 2025-03-28 08:16:55

Charles Schwab Investment Management Inc. Has $14.89 Million Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Charles Schwab Investment Management Inc. increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 4.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,979,992 shares of the biotechnology company’s stock after buying an additional 91,998 shares during the quarter. […] - 2025-03-21 07:12:57

AlphaQuest LLC Has $214,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

AlphaQuest LLC lifted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 800.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 28,442 shares of the biotechnology company’s stock after purchasing an additional 25,282 shares during the period. AlphaQuest LLC’s holdings in BioCryst Pharmaceuticals were worth $214,000 as of its most recent SEC […] - 2025-03-17 08:04:53

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Recommendation of “Moderate Buy” by Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among […] - 2025-03-14 06:58:49

BioCryst Pharmaceuticals (NASDAQ:BCRX) Coverage Initiated at Wedbush

Wedbush assumed coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) in a research report report published on Tuesday morning, MarketBeat reports. The brokerage issued an outperform rating and a $15.00 price objective on the biotechnology company’s stock. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings […] - 2025-02-28 06:54:43

HC Wainwright Reiterates “Buy” Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $30.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 258.85% from the company’s previous close. Several other […] - 2025-02-27 08:47:03

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down After Earnings Miss

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) shares gapped down prior to trading on Monday following a weaker than expected earnings announcement. The stock had previously closed at $9.21, but opened at $8.87. BioCryst Pharmaceuticals shares last traded at $8.06, with a volume of 1,452,227 shares. The biotechnology company reported ($0.13) EPS for the […] - 2025-02-26 06:21:00

Company News for Feb 25, 2025

Companies in The News Are: DPZ,WLK,BCRX,NFLX - 2025-02-25 14:21:00

BioCryst Pharma Reports Positive Data From APeX-P Study In Hereditary Angioedema

(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) Monday reported positive results from APeX-P study of Orladeyo in hereditary angioedema (HAE) patients aged between 2 and 12 years. - 2025-02-24 12:21:00

KBC Group NV Buys 4,537 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

KBC Group NV grew its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 80.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 10,198 shares of the biotechnology company’s stock after acquiring an additional 4,537 shares during the period. KBC Group NV’s holdings in BioCryst Pharmaceuticals were worth $77,000 at the end […] - 2025-02-10 18:30:56

BioCryst Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the recipient of some unusual options trading activity on Wednesday. Stock investors bought 6,158 call options on the stock. This is an increase of approximately 593% compared to the average daily volume of 888 call options. Analysts Set New Price Targets A number of equities research […] - 2025-02-07 06:47:04

BCRX institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	148,435	USD 1,472,475
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	20,076	USD 199,154 -1.6%
2025-05-08	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	267,519	USD 2,653,788
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	100,830	USD 1,000,234
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	100,830	USD 1,000,234 -1.6%
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	606	USD 6,012
Total =		638,296	USD 6,331,897

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer